# A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

> **NCT03976648** · PHASE2 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 31 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** GLPG1690

## Key facts

- **NCT ID:** NCT03976648
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-18
- **Primary completion:** 2021-04-13
- **Final completion:** 2021-04-13
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** The benefit-risk profile no longer supports continuing the studies
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976648, "A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03976648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*